TOP TEN perturbations for Q7Z5M8 (Homo sapiens)

Organism: Homo sapiens
Gene: Q7Z5M8
Selected probe(set): 237974_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q7Z5M8 (237974_at) across 5610 perturbations tested by GENEVESTIGATOR:

basal cell carcinoma study 3 / normal epidermal keratinocytes

Relative Expression (log2-ratio):4.963417
Number of Samples:4 / 2
Experimental basal cell carcinoma study 3
Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC).
Control normal epidermal keratinocytes
Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37?C in humidified air containing 5% CO2.

skin transplantation study 1 (3d) / normal skin tissue (skin grafting)

Relative Expression (log2-ratio):-4.273492
Number of Samples:6 / 8
Experimental skin transplantation study 1 (3d)
Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 3 days after surgery.
Control normal skin tissue (skin grafting)
Skin biopsy samples from healthy control subjects after breast or abdomen reduction surgery.

wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-4.252097
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; DMSO)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin.
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

stem cell differentiation study 41 (T3pi) / undifferentiated hES-T3 cell sample

Relative Expression (log2-ratio):-4.156577
Number of Samples:2 / 3
Experimental stem cell differentiation study 41 (T3pi)
Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control undifferentiated hES-T3 cell sample
Undifferentiated human embryonic stem cells T3.

ovarian tumor study 16 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):-4.1213665
Number of Samples:3 / 5
Experimental ovarian tumor study 16
Human epithelial tumor cell samples from the ovary of patients with papillary serous carcinoma. Samples were derived by laser capture microdissection (LCM).
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue.

stem cell differentiation study 41 (hES-T3 EB) / undifferentiated hES-T3 cell sample

Relative Expression (log2-ratio):-3.8541517
Number of Samples:2 / 3
Experimental stem cell differentiation study 41 (hES-T3 EB)
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype.
Control undifferentiated hES-T3 cell sample
Undifferentiated human embryonic stem cells T3.

precursor-B-ALL study 3 (E2A-PBX1) / precursor-B-ALL study 3 (MLL-rearranged)

Relative Expression (log2-ratio):3.518383
Number of Samples:6 / 5
Experimental precursor-B-ALL study 3 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (MLL-rearranged)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 3 (E2A-PBX1) / precursor-B-ALL study 3 (TEL-AML1)

Relative Expression (log2-ratio):3.497414
Number of Samples:6 / 15
Experimental precursor-B-ALL study 3 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control precursor-B-ALL study 3 (TEL-AML1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample

Relative Expression (log2-ratio):3.4819126
Number of Samples:36 / 74
Experimental precursor-B-ALL study 1 (t(1;19)(q23,q13))
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

stem cell differentiation study 46 (BMP4, inhibitors) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):-3.3843126
Number of Samples:3 / 3
Experimental stem cell differentiation study 46 (BMP4, inhibitors)
Extraembryonic cells differentiated from WA09 cells in chemically defined medium supplemented with BMP4 and inhibitors of activin and FGF2. Differentiation was performed in the absence of feeders cells and serum. Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then in CDM supplemented with BMP4 (10 ng/ml), an inhibitor of Alk4/5/7 receptors (type I Activin receptor-like kinase), SB431542 (10uM), and an inhibitor of FGF receptors, SU5402 (10uM), for 3-4 days.
Control normal embryonic stem cell sample (WA09)
WA09 embryonic stem cells cultivated in chemically defined medium (CDM). Cells were first grown on fibronection-coated plates in CDM supplemented with activin (10 ng/ml) and FGF2 (12 ng/ml) for two days and then further cultivated in CDM alone for 3-4 days. CDM consists of 50% Iscove?s Modified Dulbecco?s Medium and 50% F12 Ham?s nutrient mixture. It is devoid of serum and supplemented with insulin (7 ug/ml), transferrin (15 ug/ml), monothioglycerol (450 uM) and serum albumin (5 mg/ml).